DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC50 = 21.83 µM) and HL-60 (IC50 = 19.14 µM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies[1].
Molekulargewicht:
355.23
Formel:
C18H15BrN2O
Target-Kategorie:
CDK,Checkpoint Kinase (Chk),Wee1
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
